ANTI-CD33 MONOCLONAL-ANTIBODY M195 FOR THE THERAPY OF MYELOID-LEUKEMIA

被引：14

作者：

CARON, PC ^{[1
]}

SCHEINBERG, DA ^{[1
]}

机构：

[1] MEM SLOAN KETTERING CANC CTR,DEPT MED,CLIN IMMUNOL SERV,NEW YORK,NY 10021

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

MONOCLONAL ANTIBODY; M195; ACUTE MYELOGENOUS LEUKEMIA; HUMANIZED ANTIBODY; RADIOLABEL; CD33;

D O I：

10.3109/10428199309064254

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Leukemia is well suited for monoclonal antibody therapy due to the accessible, differentiation antigens that characterize stages of maturation. In this paper, we describe the use of radio-labeled M195, a murine IgG2a, anti-CD33 monoclonal antibody, that can be used to effectively cytoreduce AML cells in relapsed patients when tumor burden is high; or to eliminate minimal residual disease and lengthen disease-free survival in patients with APL in remission. To decrease the likelihood of immunogenicity, a humanized IgG1 version of M195 was constructed that demonstrated a higher avidity and improved effector function than the parent murine antibody. Preliminary results of the first trial in AML using a humanized antibody showed specific bone marrow targeting without an immunogenic response.

引用

页码：1 / 6

页数：6

共 25 条

[1]

Foon K.A., Gale R.P., Therapy of acute my-elogenous leukemia, Blood Rev., 6, pp. 15-25, (1992)

[2]

Scheinberg D.A., Monoclonal antibodies in the treatment of myelogenous leukemias, Leukemia: Advances Research and Treatment, pp. 213-232, (1993)

[3]

Grossbard M.L., Press O.W., Appelbaum F.R., Bemstein I.D., Nadler L.M., Monoclonal antibody-based therapies of leukemia and lymphoma, Blood, 80, pp. 863-878, (1992)

[4]

Tanimoto M., Scheinberg D.A., Cordon-Cardo C., Huie D., Clarkson B.D., Old L.J., Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195, Leukemia (Baltimore), 3, pp. 339-348, (1989)

[5]

Scheinberg D.A., Tanimoto M., McKenzie S., Strife A., Old L.J., Clarkson B.D., Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia, Leukemia (Baltimore), 3, pp. 440-445, (1989)

[6]

Lemoli R.M., Gasparetto C., Scheinberg D.A., Moore M.A.S., Clarkson B.D., Gulati S.C., Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination, Blood, 77, pp. 1829-1836, (1991)

[7]

Scheinberg D.A., Lovett D., Divgi C.R., Graham M.C., Berman E., Pentlow K., Feirt N., Finn R.D., Clarkson B.D., Gee T.S., Larson S.M., Oettgen H.F., Old L.J., A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide, J. Clin. Oncol., 9, pp. 478-490, (1991)

[8]

Schwartz M.A., Lovett D.R., Redner A., Finn R.D., Graham M.C., Divgi C.R., Dantis L., Gee T.S., An-Dreeff M., Old L.J., Larson S.M., Scheinberg D.A., Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias, J. Clin. Oncol., 11, pp. 294-303, (1993)

[9]

Co M.S., Avdalovic N.M., Caron P.C., Avdalovic M.V., Scheinberg D.A., Queen C., Chimeric and humanized antibodies with specificity for the CD33 antigen, J. Immunol., 148, pp. 1149-1154, (1992)

[10]

Hale G., Clark M.R., Marcus R., Winter G., Dyer M.J.S., Phillips J.M., Riechmann L., Waldmann H., Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H, Lancet, 2, pp. 1394-1399, (1988)

← 1 2 3 →